Independent Data Monitoring Committee Clause Samples
An Independent Data Monitoring Committee (IDMC) clause establishes a group of experts who are separate from the study sponsors and investigators, tasked with overseeing the safety and efficacy data during a clinical trial. This committee regularly reviews interim data, monitors for adverse events, and can recommend modifications or early termination of the study if significant concerns arise. The core function of this clause is to ensure unbiased oversight and participant safety, thereby maintaining the integrity of the trial and protecting subjects from undue risk.
Independent Data Monitoring Committee. (IDMC) - a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from an ongoing clinical trial. The IDMC advises the sponsor regarding the continuing safety of current participants and those yet to be recruited, as well as the continuing validity and scientific merit of the trial. The Contractor may be required to use relevant members from an established BARDA IDMC or to organize an independent IDMC. The Contractor will submit the composition of the IDMC to the Contracting Officer’s Representative for review. All phase III clinical trials must be reviewed by IDMC; other trials may require IDMC oversight as well. Please refer to FDA Guidance for Clinical Trials Sponsors “Establishment and Operation of Clinical Trial Data Monitoring Committees”. The Government retains the right to place a nonvoting member on the IDMC. When a safety monitoring entity is organized, a description of it, its charter or operating procedures (including a proposed meeting schedule and plan for review of adverse events), and roster and curriculum vitae from all members must be submitted to the Government before Visterra, Inc. HHSO100201500018C enrollment starts. Additionally, the Contractor must submit written summaries of all reviews conducted by the monitoring group to the Government within 30 days of reviews or meetings.
Independent Data Monitoring Committee. An Independent Data Monitoring Committee (IDMC) will be established comprising of at least 5 independent experts (2 medical oncologists, two immunotherapists and one statistician) who have no conflict of interest and agree with the outline of the protocol. None of the members of the IDMC should be among the participants in the trial. The committee will meet when the interim analysis has been performed by the statistician of the trial. All possible aspects of the trial will be the subject of the interim analysis (see section 11.3.
Independent Data Monitoring Committee. An IDMC will not be utilized in this study. Sponsor will monitor safety in accordance with ICH- GCP E6 (R2) guidelines.
Independent Data Monitoring Committee. “IDMC”). OPKO will establish an IDMC for each Trial if not already established, which will be governed by a charter substantially in the form to be agreed upon by the Parties within *** days of the Effective Date (the “IDMC Charter”). For clarity, the IDMC Charter will specify the number of members of the IDMC, the qualifications of such members, the experience of the chairman of the IDMC, details regarding open and closed sessions, including who can attend any such sessions, and information that the IDMC may share with the Parties, including that efficacy will not be disclosed to either Party until the IDMC has approved such data. OPKO will communicate any decision of the IDMC to the JDC within five (5) Business Days of such decision. OPKO will ensure that the IDMC is provided with all information and data that it requires as specified in the IDMC Charter, and Pfizer will reasonably cooperate with OPKO in such regard. OPKO will ensure that all members of the IDMC have any licenses, certifications and/or accreditations required by Applicable Laws; and understand the Development Plan and their obligation to comply therewith and all Applicable Laws in conducting such Trial(s). Any such representations and warranties will be made for the benefit of OPKO and Pfizer as third party beneficiaries. OPKO will ensure that each member completes the Financial Disclosure Form. For clarity, if any of the foregoing individuals do not complete such Financial Disclosure Form, such individuals may not participate in the IDMC.
Independent Data Monitoring Committee. An IDMC has been established for this study and specific guidelines on the operation and purpose of the IDMC is documented in a Charter. The committee includes at least 3 members, including a statistician and medical oncologists experienced in the treatment of EOC. Safety review meetings will be held as per the IDMC charter and as needed if any unexpected safety signals emerge during the study. The IDMC will be responsible for independently evaluating safety data of patients enrolled to the study. Decisions on study termination, amendment of the protocol, or cessation of patient recruitment will be made after recommendations from the IDMC have been assessed by the Sponsor.